The Pharmacist-Developed Tool Helping Mitigate Drug Shortages
In a world where drug shortages are one of the most pressing issues for pharmacy businesses, there are certain tools making a significant difference in helping patients access their drugs at the pharmacy.
FDA Approves Hydrocortisone Oral Solution for Adrenocortical Insufficiency
The replacement therapy is indicated for patients 5 years and older, marking the first approval for an oral solution form of hydrocortisone.
HHS Stops Funding Moderna’s Bird Flu Vaccine, Cancels $590 Million Award
Currently under development, the manufacturer’s investigational pandemic influenza vaccine is designed to target the H5 avian influenza virus, or bird flu.
How iA is at the Forefront of an Evolving Pharmacy Landscape
Alecia Lashier, chief automation officer and executive vice president at iA, discusses transformations in the pharmacy industry and how they’ve impacted pharmacists and their businesses.
Pathology of Nonadherence Does Not Accurately Represent Structural Barriers to Care
The use of the terminology can alter the meaning when assigned to patients’ behaviors, unintentionally implying that barriers such as poverty or systemic racism are due to poor behavior or efforts.
Sustained Midlife Weight Loss Linked With Long-Term Health Benefits
The data show a decrease in all-cause mortality for sustained midlife weight loss achieved without surgical or pharmacological interventions.
Q&A: Support, Reimbursement Key For Expanded Pharmacy Services | PQA 2025
Michael Hegener, PharmD, BCACP, discusses how workforce development can best address the evolving knowledge, skills, and abilities needed in community pharmacy practice.
PBM Reform Necessary for Access to Medicare Part D Drugs
Researchers evaluated PBM reimbursement practices in Medicare and whether they resulted in out-of-pocket cost increases for Part D beneficiaries.
Q&A: Pharmacy Success Lies in Service, Payment Reform | PQA 2025
Micah Cost, PharmD, MS, CAE, discusses the biggest issues currently impacting the pharmacy profession.
Q&A: Workflow Tools Can Help Pharmacists Improve Patient Outcomes | PQA 2025
Kaitlin Bates, PharmD, discusses the results of implementing a program used to support standardized pharmacy quality measures.
Development of AI is Essential to Pharmacy Education
Researchers conducted a scoping review to evaluate conversational AI agents and their use in pharmacy education.
FDA Grants Interchangeability Designation to Adalimumab-Bwwd for Humira
This designation follows Hadlima’s low-concentration prefilled syringes and single-dose vials, which were designated in June 2024.
Infections for Measles, Bird Flu, and Pertussis Increase in 2025
Pharmacists play a critical role in vaccination and education for patients about the evolving infectious disease landscape.
Behavioral Science Methods Failed to Improve Medication Adherence
Researchers aimed to estimate the impact of using behavioral science principles within communication intended for hypertension medication adherence.
FDA Approves Ustekinumab-Hmny as Biosimilar to Stelara
Ustekinumab is a medication used to treat and manage inflammatory conditions, including psoriasis, psoriatic arthritis, and inflammatory bowel disease.
Q&A: Workflow Changes Needed as Pharmacies Take on Clinical Roles | PQA 2025
Michael Hegener, PharmD, BCACP, discusses what workflow changes are essential to support the expansion of patient care services in community pharmacies.
Hospital-Pharmacy Relationship Drives Generic Drug Use
Researchers explored how relationships between physicians, pharmacists, and patients are associated with the use of generic drugs in Japanese pharmacies.
Q&A: Pharmacists Bridge the Gap in Safe Medication Disposal | PQA 2025
Mitchell Barnett, PharmD, MS, discusses what lessons can be learned from a community pharmacy drug disposal program.
How Community Pharmacies Can Proactively Identify Drug Shortages
David Swenson, RPh, discussed drug shortage technology that his company is helping bring to community pharmacies across the country.
Study Finds Link Between Prenatal Cardiometabolic Factors and Hypertension for Children
By protecting pregnant patients from cardiometabolic risk factors, healthier blood pressure can be promoted for children.
Q&A: How Pressure in the Marketplace Could Enforce PBM Reform
PBM expert Antonio Ciaccia, president of 3 Axis Advisors and CEO of 46brooklyn Research, discussed recent events in the pharmacy benefits industry and how it is moving toward PBM reform.
Q&A: How PBM Practices Were Uncovered in the Ohio Medicaid Program
Antonio Ciaccia, President of 3 Axis Advisors, CEO of 46brooklyn Research, and pharmacy benefits expert, discussed his role in uncovering PBM practices and pharmacy consulting.
Prenatal Use of Triptans Does Not Increase Risk of Autism, ADHD in Children
Triptans are often a first-line treatment for migraine and can be used to treat menstrual migraine and cluster headaches.
Impact of IRA Insulin Cap on Rates of Persistence to Basal Insulin | PQA 2025
A conversation with Razanne Oueini, PharmD, MSc, CPHQ, senior manager of Performance Measurement at PQA, at PQA 2025.
Dupilumab Can Safely Treat Atopic Dermatitis During Pregnancy
Researchers explored the current evidence regarding women’s reactions to biological therapies for treating atopic dermatitis during pregnancy.
Majority of Americans Understand Risks of Increased Acetaminophen Usage
Acetaminophen exposure can increase the risk of perforation, ulceration, bleeding, heart failure, hypertension, and chronic kidney disease.
Q&A: The New Technology Helping Pharmacies Facilitate Drug Shortages
David Swenson, RPh, Founder and CEO of ShortStop Rx, joined Drug Topics to discuss the CCT Rx Shortage Solutions technology and how it’s helping combat drug shortages in the US.
FDA Grants Expanded Interchangeability Designation to Yuflyma
Adalimumab-aaty (Yuflyma) prefilled syringes and autoinjectors are now fully interchangeable with the reference product adalimumab (Humira) across marketed dosage forms and strengths.
FDA Approves Roflumilast Foam For Plaque Psoriasis of Scalp, Body
The supplemental new drug application for roflumilast (Zoryve) is approved for adult and pediatric patients 12 years and older.
FDA Approves Mepolizumab for Treatment of COPD Exacerbations
Approval comes from positive results in the MATINEE and METREX phase III trials, with data showing a significant reduction in annual rates of COPD exacerbations among patients.
